Payment overview · 2025
General Payments
$555.89
32 reported records · 15 companies
Healthcare provider profile · identity verified
Mark B Alrais, M.D
Allopathic & Osteopathic Physicians|Family Medicine · SAINT CLAIR SHORES, MI · NPI 1083875702
Verified facts
What the public records show
CMS Open Payments records show Mark B Alrais, M.D received $555.89 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.73 | 18.8% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.42 | 14.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.89 | 11.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.13 | 11.4% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.21 | 6.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.99 | 5.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.52 | 5.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.64 | 4.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.30 | 4.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.59 | 3.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.85 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.41 | 3.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.15 | 3.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.39 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.67 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $555.89 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.42 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $80.42 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.89 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.77 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.67 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
184 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1013 | 333 |
| Losartan Potassium | Losartan Potassium | 549 | 178 |
| Omeprazole | Omeprazole | 506 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 467 | 156 |
| Lisinopril | Lisinopril | 444 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 103 |
| Fluticasone Propionate | Fluticasone Propionate | 316 | 126 |
| Simvastatin | Simvastatin | 256 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 239 | 73 |
| Furosemide | Furosemide | 210 | 85 |
| Carvedilol | Carvedilol | 202 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 71 |
| Eliquis | Apixaban | 184 | 49 |
| Prednisone | Prednisone | 178 | 129 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 56 |
| Metformin Hcl Er | Metformin Hcl | 173 | 58 |
| Jardiance | Empagliflozin | 161 | 45 |
| Gabapentin | Gabapentin | 152 | 64 |
| Allopurinol | Allopurinol | 147 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 55 |
| Montelukast Sodium | Montelukast Sodium | 123 | 47 |
| Metformin Hcl | Metformin Hcl | 120 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 49 |
| Trazodone Hcl | Trazodone Hcl | 117 | 45 |
| Famotidine | Famotidine | 114 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 31 |
| Meloxicam | Meloxicam | 93 | 36 |
| Alendronate Sodium | Alendronate Sodium | 91 | 30 |
| Potassium Chloride | Potassium Chloride | 86 | 37 |
| Glipizide | Glipizide | 82 | 27 |
| Methocarbamol | Methocarbamol | 82 | 45 |
| Alprazolam | Alprazolam | 72 | 29 |
| Nifedipine Er | Nifedipine | 71 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 27 |
| Tramadol Hcl | Tramadol Hcl | 67 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 18 |
| Ozempic | Semaglutide | 61 | 19 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 52 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 21 |
| Celecoxib | Celecoxib | 49 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 14 |
| Spironolactone | Spironolactone | 48 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 14 |
| Sertraline Hcl | Sertraline Hcl | 44 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 15 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Diazepam | Diazepam | 42 | 15 |
| Folic Acid | Folic Acid | 42 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 30 |
| Ezetimibe | Ezetimibe | 39 | 15 |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Mounjaro | Tirzepatide | 39 | 12 |
| Cephalexin | Cephalexin | 38 | 28 |
| Azithromycin | Azithromycin | 36 | 32 |
| Trulicity | Dulaglutide | 36 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 30 |
| Nystatin | Nystatin | 32 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 12 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 19 |
| Methylprednisolone | Methylprednisolone | 29 | 28 |
| Midodrine Hcl | Midodrine Hcl | 29 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 24 |
| Atenolol | Atenolol | 27 | 11 |
| Chlorthalidone | Chlorthalidone | 27 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | 11 |
| Ammonium Lactate | Ammonium Lactate | 25 | 13 |
| Baclofen | Baclofen | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 25 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 22 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Torsemide | Torsemide | 24 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 18 |
| Ofloxacin | Ofloxacin | 22 | 21 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 16 |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | 11 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Cefuroxime | Cefuroxime Axetil | 18 | 18 |
| Ramipril | Ramipril | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 13 |
| Naproxen | Naproxen | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $555.89 · 32 records | Novo Nordisk Inc | Auvelity, Cologuard Collection Kit, EVENITY, FUROSCIX, INSPIRE, JATENZO, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, STRENSIQ, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, ZAVZPRET, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error